By Nicholas G. Miller
BeOne Medicines agreed to sell its royalty rights on the non-China sales of cancer drug Imdelltra to Royalty Pharma for up to $950 million.
The drug is developed by biopharmaceutical company Amgen, which has a stake in BeOne.
BeOne will receive an upfront payment of $885 million, with the option to sell remaining royalties for up to $65 million. The company will receive a portion of royalties on annual sales above $1.5 billion.
BeOne will retain royalty rights to other assets under its partnership with Amgen.
Write to Nicholas G. Miller at nicholas.miller@wsj.com.
(END) Dow Jones Newswires
August 25, 2025 06:34 ET (10:34 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
The articles, information, and content displayed on this webpage may
include materials prepared and provided by third parties. Such
third-party content is offered for informational purposes only and
is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the
accuracy, completeness, timeliness, or reliability of any third-party
content displayed on this site. The views and opinions expressed in
third-party content are those of the respective authors and do not
necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays
in this content, nor for any actions taken in reliance thereon.
Users are advised to exercise their own judgment and seek independent
financial advice before making any decisions based on such content.
The third-party providers of this content are not affiliated with
Morningstar, and their inclusion on this site does not imply any
form of partnership, agency, or endorsement.